Picture [MSC] – The Mass Spectrometry Web Portal 600x80px
Document › Details

Arvinas, LLC. (11/15/17). "Press Release: Arvinas Expands Strategic License Agreement with Genentech". New Haven, CT.

Organisations Organisation Arvinas Inc.
  Group Arvinas (Group)
  Organisation 2 Genentech Inc.
  Group Roche (Group)
Products Product PROTAC technology (proteolysis targeting chimeric molecules)
  Product 2 drug development
Index terms Index term Roche–Arvinas: protein degradation drugs, 201711– strategic license expansion for PROTAC technology to Genentech
  Index term 2 Roche–Arvinas: protein degradation drugs, 201510– strategic license multi-year for PROTAC technology to Genentech
Persons Person Houston, John (Arvinas 201711 CEO)
  Person 2 Crews, Craig (Yale Univ 201205 Professor Molecular, Cellular + Developmental Biology + Prof Chemistry + Pharmacology)

Expansion of 2015 agreement brings total deal value to potentially exceed $650 million

Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced it has expanded its ongoing license agreement with Genentech, a member of the Roche Group, for the development of new therapeutics using Arvinas’ novel PROTAC technology. The multi-year strategic license agreement, initiated in October 2015, will encompass additional disease targets and expand the collaboration.

Under the revised terms of the agreement, Arvinas is eligible to receive development and commercialization milestone payments in excess of $650 million based on achievement of certain predetermined milestones. In addition, Arvinas is eligible to receive tiered-royalties on sales of products resulting from the license agreement. Full financial terms have not been disclosed.

“Genentech’s decision to expand our original agreement to include additional disease targets shows the promise seen in our first two years together and further supports our targeted protein degradation platform as a novel drug modality to treat a broad array of diseases,” said John Houston, Ph.D., President and Chief Executive Officer of Arvinas. “This expansion also supports our initial decision to work with Genentech in 2015 and we look forward to this growing collaboration.”

The PROTAC Platform offers potential improvements over traditional small molecule inhibitors using the ubiquitin and proteasome system within a cell to degrade disease causing proteins. By removing target proteins directly rather than inhibiting them, PROTACs can provide multiple advantages over small molecule inhibitors, which can require high systemic exposure to achieve sufficient inhibition, often resulting in toxic side effects and eventual drug resistance.

About Arvinas

Arvinas is a pharmaceutical company focused on developing new small molecules ? known as PROTACs (PROteolysis TArgeting Chimeras) ? aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, facilitating the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets. For more information, visit


Arvinas Media Contact
Ian Stone

Arvinas Investor Contact
Beth DelGiacco

Record changed: 2017-11-26


Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px

More documents for Arvinas (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 600x60px

» top


Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Picture [LSE] – The Business Web Portal 120x600px Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 120x240px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px